Skip to main content
FinSpry Logo
FinSpry
TSHA logo
TSHA
(NASDAQ)
Taysha Gene Therapies, Inc.
$5.83-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Taysha Gene Therapies (TSHA) Stock Price & Financial Analysis

Taysha Gene Therapies Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$5.47 - $5.88
52-Week High$7.30
52-Week Low$2.53
Open$5.51
Volume2.44M
Average Volume (3M)3.68M
Market Cap2.14B
Shares Outstanding366.63M
Price to Sales (P/S)286.10
Price to Book (P/B)10.09
EV/EBITDA-14.61
Revenue (TTM)7.47M
Net Income (TTM)-129.88M
Free Cash Flow (TTM)-115.33M
EPS (TTM)$-0.39
Profit Margin-1738.40%
Operating Margin-1774.37%
Return on Equity (ROE)-61.28%
Debt to Equity0.08
50-Day MA$6.01
200-Day MA$5.23
52-Week Change116.73%
Annual Dividend$0.00
Dividend Yield0.00%

Frequently Asked Questions About Taysha Gene Therapies

What is the current stock price for TSHA?

As of the latest trading session, TSHA stock trades at $5.83. The 52-week range is $2.53–$7.30, with a day range of $5.47–$5.88.

What is the P/E ratio for TSHA?

The P/E ratio (Price-to-Earnings) for TSHA is shown in the Key Statistics section. This valuation metric helps compare Taysha Gene Therapies, Inc. to industry peers.

Does TSHA pay dividends?

Taysha Gene Therapies does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for TSHA?

Based on 11 analysts, the consensus for TSHA is Buy.

What is the market cap of TSHA?

Taysha Gene Therapies's market capitalization is $2.14B, classifying it as a mid-cap company. Taysha Gene Therapies operates in the Healthcare sector within the Biotechnology industry.